Kognitic
2020 April 21, 2020

Tepotinib vs Capmatinib: A Race for Approval

1 min read
Tepotinib vs Capmatinib: A Race for Approval

Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor.

The two continue to strive for approval in the United States. Kognitic‘s platform highlights the timeline for ongoing trials for both these drugs below. The approval for Tepotinib comes from Merck KGaA’s ongoing Vision trial.

← Back to all posts

Kognitic enables faster, more confident decisions

Not just more data

Every week spent reconciling fragmented intelligence is a week your competitors are already acting on it. That is the cost of delay.

Schedule a Landscape Audit Or explore the platform →